corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen. Since our inception in 2000, we have treated over 21,000 patients globally and have grown to over 1,000 employees with operations in the United States, Europe, the Middle East and Asia.

corporate presentation
3
FDA-approved indications
21,000+
patients treated through September 2021
$464M
annual net revenues (2020)
$132M
annual R&D investments (2020)
4
phase 3 trials in new indications
view all

latest filings

date filing type filing download
January 26, 2022 SC 13G/A Amended Statement of Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 12, 2022 4 Statement of Changes in Beneficial Ownership
January 10, 2022 8-K Current report filing
January 05, 2022 4 Statement of Changes in Beneficial Ownership
December 30, 2021 8-K Current report filing
December 07, 2021 8-K Current report filing
November 29, 2021 4 Statement of Changes in Beneficial Ownership
November 03, 2021 4 Statement of Changes in Beneficial Ownership
October 28, 2021 8-K Current report filing
October 28, 2021 10-Q Quarterly Report
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.